Interestingly, although independent from MTA1, pterostilbene also downregulated the AR levels (Figure 5A and 5B), further strengthening its potential as a suitable chemopreventive agent to reduce the risk of prostate cancer. Here, MTA1 is linked to prostate carcinoma.